For US Healthcare Professionals Only Important Safety Information Prescribing Information Request a Rep
Menu

KENGREAL® (cangrelor)
Frequently Asked Questions (FAQs)

See the most common topics on clinicians’ minds.

Home > Resources > FAQs

Click on the + following each question to reveal the answer.

KENGREAL safety

KENGREAL is contraindicated in patients with significant active bleeding or in patients who have a known hypersensitivity (eg, anaphylaxis) to cangrelor or any component of the product.1

See Clinical Safety Data

KENGREAL cases

KENGREAL can be considered in a range of PCI cases in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.1

Explore KENGREAL Case Studies

KENGREAL dosing & transition

Reconstitute

Reconstitute the contents of the vial immediately before dilution1:

  • Add 5 mL of Sterile Water for Injection to one 50-mg vial.
  • Swirl gently until all material is dissolved; avoid vigorous mixing.
  • Allow any foam to settle.

Reconstituted KENGREAL will be a clear, colorless to pale yellow solution. Product should not contain particulate matter.

Do not use reconstituted solution of KENGREAL without dilution.

arrow icon

Dilute

Dilution can be in either 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP1:

  • Add contents from one reconstituted vial to one 250-mL saline or dextrose bag and mix thoroughly.
  • Final concentration = 200 mcg/mL; sufficient for at least 2 hours of dosing. Patients 100 kg and over require a minimum of 2 bags.

Diluted KENGREAL is stable at room temperature for up to 12 hours in 5% dextrose injection and 24 hours in normal saline. Discard any unused portion of reconstituted solution remaining in the vial.

Be sure to read the full preparation instructions in the KENGREAL Dosing & Administration Guide — and watch the KENGREAL preparation video, too.

USP=United States Pharmacopeia.

Administer 180 mg of ticagrelor at any time during KENGREAL infusion or immediately at the end of infusion.1

See KENGREAL Dosing
  • Administer 60 mg of prasugrel immediately after discontinuation of KENGREAL1
  • Do not administer prasugrel prior to discontinuation of KENGREAL1
See KENGREAL Dosing
  • Administer 600 mg of clopidogrel immediately after discontinuation of KENGREAL1
  • Do not administer clopidogrel prior to discontinuation of KENGREAL1
See KENGREAL Dosing

Still have questions?

Get in touch with a KENGREAL rep to find the answers.

Request a Rep
View More

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Please see Full Prescribing Information.

Indication

KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Reference: 1. KENGREAL® (cangrelor) Prescribing Information. 2022.

Back
to top